Pimavanserin Tartrate Patent Expiration
Pimavanserin Tartrate is used for treating symptoms of neurodegenerative diseases such as Parkinson's psychosis and hallucinations. It was first introduced by Acadia Pharmaceuticals Inc
Pimavanserin Tartrate Patents
Given below is the list of patents protecting Pimavanserin Tartrate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Nuplazid | US10449185 | Formulations of pimavanserin | Aug 27, 2038 | Acadia Pharms Inc |
| Nuplazid | US10646480 | Formulations of pimavanserin | Aug 27, 2038 | Acadia Pharms Inc |
| Nuplazid | US10849891 | Formulations of pimavanserin | Aug 27, 2038 | Acadia Pharms Inc |
| Nuplazid | US11452721 | Formulations of pimavanserin | Aug 27, 2038 | Acadia Pharms Inc |
| Nuplazid | US10517860 | Combination of pimavanserin and cytochrome P450 modulators | Mar 23, 2037 | Acadia Pharms Inc |
| Nuplazid | US10953000 | Combination of pimavanserin and cytochrome P450 modulators | Mar 23, 2037 | Acadia Pharms Inc |
| Nuplazid | US7601740 | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases | Apr 29, 2030 | Acadia Pharms Inc |
| Nuplazid | US7732615 | N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms | Jun 03, 2028 | Acadia Pharms Inc |
| Nuplazid | US7659285 | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases | Aug 24, 2026 | Acadia Pharms Inc |
| Nuplazid | US7923564 | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its tartrate salt and crystalline forms | Sep 26, 2025 | Acadia Pharms Inc |
| Nuplazid | US10028944 | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Jan 15, 2024
(Expired) | Acadia Pharms Inc |
| Nuplazid | US8618130 | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Jan 15, 2024
(Expired) | Acadia Pharms Inc |
| Nuplazid | US8921393 | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Jan 15, 2024
(Expired) | Acadia Pharms Inc |
| Nuplazid | US9566271 | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Jan 15, 2024
(Expired) | Acadia Pharms Inc |
| Nuplazid | US9765053 | Methods of treatment using selective 5-HT2A inverse agonists |
Jul 27, 2022
(Expired) | Acadia Pharms Inc |
| Nuplazid | US7115634 | 4-aminopiperidine and their use as a medicine |
Oct 06, 2021
(Expired) | Acadia Pharms Inc |
| Nuplazid | US6756393 | Azacyclic compounds |
Mar 06, 2021
(Expired) | Acadia Pharms Inc |
| Nuplazid | US6815458 | Azacyclic compounds |
Mar 06, 2021
(Expired) | Acadia Pharms Inc |
| Nuplazid | US9296694 | Azacyclic compounds |
Mar 06, 2021
(Expired) | Acadia Pharms Inc |
| Nuplazid | US7858789 | Derivatives of 4-aminopiperidine and their use as a medicament |
Dec 13, 2020
(Expired) | Acadia Pharms Inc |
| Nuplazid | US8110574 | Derivatives of 4-aminopiperidine and their use as a medicament |
Dec 13, 2020
(Expired) | Acadia Pharms Inc |
Pimavanserin Tartrate's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List